A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

(2011) Stuart L. Emanuel et al.   mAbs

The insulin-like growth factor-I receptor as an oncogene

(2011) Haim Werner et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

CETUXIMAB: From Bench to Bedside

(2010) B. Vincenzi et al.   CURRENT CANCER DRUG TARGETS

A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

(2010) Renuka Iyer et al.   EXPERT OPINION ON PHARMACOTHERAPY

Gefitinib for the treatment of non-small-cell lung cancer

(2010) Lynn Campbell et al.   EXPERT OPINION ON PHARMACOTHERAPY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity

(2010) Jianying Dong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia

(2010) Pierre Laneuville et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Testing in Li-Fraumeni Syndrome: Uptake and Psychosocial Consequences

(2010) Chantal R.M. Lammens et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

(2010) Jennifer S. Michaelson et al.   mAbs

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Stability engineering of scFvs for the development of bispecific and multivalent antibodies

(2010) Brian R. Miller et al.   PROTEIN ENGINEERING DESIGN & SELECTION

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients

(2009) V. Ludovini et al.   ANNALS OF ONCOLOGY

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

(2009) C. Desbois-Mouthon et al.   CLINICAL CANCER RESEARCH

Integration of panitumumab into the treatment of colorectal cancer

(2009) Cristina Gravalos et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy

(2009) J. Veeken et al.   CURRENT CANCER DRUG TARGETS

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Bispecific antibodies for cancer therapy

(2009) Nurit Hollander   Immunotherapy

Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties

(2009) Adam Doern et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors

(2009) Peiming Ma et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis

(2009) S. Kaulfuss et al.   MOLECULAR CANCER THERAPEUTICS

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

(2008) E. Buck et al.   CANCER RESEARCH

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

(2008) K. Yonesaka et al.   CLINICAL CANCER RESEARCH

Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

(2008) Daniel J. Freeman et al.   Clinical Colorectal Cancer

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

(2008) J. Rodon et al.   MOLECULAR CANCER THERAPEUTICS

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

(2008) P. Haluska et al.   MOLECULAR CANCER THERAPEUTICS

Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

(2008) Daisuke Takahari et al.   ONCOLOGY

EGFR-targeted therapies in lung cancer: predictors of response and toxicity

(2008) Rebecca Suk Heist et al.   PHARMACOGENOMICS

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE